Host Genes and HIV: The Role of the Chemokine Receptor Gene CCR5 and Its Allele (Δ32 CCR5)

Janet M. McNicholl, Dawn K. Smith, Shoukat H. Qari, and Thomas Hodge
Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Since the late 1970s, 8.4 million people worldwide, including 1.7 million children, have died of AIDS, and an estimated 22 million people are infected with human immunodeficiency virus (HIV)(1). During 1995 and 1996, major clinical and laboratory discoveries regarding HIV pathogenesis provided new hope for the prevention and treatment of HIV infection. One major discovery was that members of the chemokine receptor family serve as cofactors for HIV entry into cells. We describe the role of allelic polymorphism in the gene coding for the CCR5 chemokine receptor with regard to susceptibility to and disease course of HIV infection. We also examine the effect of this discovery on medical and public health practices.
deletion (20-22), no cases of HIV infection had been reported in studies of more than 60 persons homozygous for the CCR5 32 bp deletion. Presence of one copy of the deleted CCR5 gene also influences the course of disease as the onset of AIDS occurs later for some heterozygous persons than for those homozygous for the wild type CCR5 (12,17-19,23). The discovery of the role of CCR5 alleles has prompted studies of the possible role of many other host genes in HIV infection (24-26).

**What Are Chemokine Receptors?**

Chemokine receptors are cell surface proteins that bind small peptides called chemokines (27). Chemokines can be classified into three groups based on the number and location of conserved cysteines: C, CC, and CXC. Chemokine receptors are grouped into families on the basis of the chemokine ligands they bind: CC, CXC, or both (27; Table 1). Some receptors are promiscuous, while others are selective in terms of ligand binding. The receptors are widely distributed on hematopoietic and other cells, but the Duffy antigen of erythrocytes (DARC) is the only member expressed on cells of erythroid lineage. Several human chemokine receptors have been classified as such on the basis of similarity of gene sequences and predicted protein structures, but their ligands have not been identified (orphan receptors). Among these is the recently identified TER1 gene (28).

The characteristic feature of all chemokine receptors is a serpentine 7 transmembrane-spanning domain structure, which is shared with other receptors; e.g., the rhodopsin and the thyrotrophin receptors (Figure 1). Extracellular portions are involved in chemokine binding, while intracellular portions are involved in cell signaling. The effect of receptor-ligand interactions is usually mediated through G-protein coupled interactions; results in alterations in cell

**Table 1. Human chemokine receptors**

<table>
<thead>
<tr>
<th>Receptors (Old names)</th>
<th>C-C Chemokines</th>
<th>C-X-C Chemokines</th>
<th>Predominant expression/Tissue distribution</th>
<th>Chromosome location</th>
<th>GenBank Acc. #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CC Receptors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCR1 (CC CKR1)</td>
<td>MIP-1α, β, RANTES, MCP-3</td>
<td></td>
<td>monocytes, T cells</td>
<td>3p21</td>
<td>L10918</td>
</tr>
<tr>
<td>CCR2A (MCP-1Ra)</td>
<td>MCP-1</td>
<td></td>
<td>T cells, basophils</td>
<td>3p21</td>
<td>U03882</td>
</tr>
<tr>
<td>CCR2B (MCP-1Rb)</td>
<td>MCP-1, 3, 4</td>
<td></td>
<td>monocytes, HIV-1 (NSI)</td>
<td></td>
<td>U03905</td>
</tr>
<tr>
<td>CCR3 (CKR3)</td>
<td>Eotaxin, RANTES, MCP-2,3,4</td>
<td></td>
<td>eosinophil, basophils, microglial cells, and possibly monocytes; little expression in peripheral blood T-lymphocytes or dendritic cells</td>
<td>3p21</td>
<td>U28694</td>
</tr>
<tr>
<td>CCR4</td>
<td>TARC</td>
<td></td>
<td>activated T cells wide: CD4+ and CD4- cells, monocytes, macrophages, dendritic cells, B cells; other tissues, e.g., brain, lung, spleen</td>
<td>3p24</td>
<td>X85740</td>
</tr>
<tr>
<td>CCR5 (CC CKR5)</td>
<td>RANTES, MIP-1α, β</td>
<td></td>
<td>monocytes, dendritic cells, microglial cells, T cells</td>
<td>3p21</td>
<td>U57840</td>
</tr>
<tr>
<td><strong>CXC Receptors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CXCR1 (IL-8 RA)</td>
<td>IL-8</td>
<td></td>
<td>neutrophils, NK cells</td>
<td>2q35</td>
<td>M68932</td>
</tr>
<tr>
<td>CXCR2 (IL-8 RB)</td>
<td>IL-8, MGS, gro-α, NAP-2, IP-10, ENA-78, Mig</td>
<td></td>
<td></td>
<td></td>
<td>M73969</td>
</tr>
<tr>
<td>CXCR3</td>
<td>IP-10, Mig, SDF-1</td>
<td></td>
<td>activated T cells wide: CD4+ and CD4- cells, monocytes, macrophages, dendritic cells, B cells; other tissues, e.g., brain, lung, spleen</td>
<td>2q21</td>
<td>X95876</td>
</tr>
<tr>
<td>CXCR4 (Fusin, LESTR, HUMSTR)</td>
<td>SDF-1</td>
<td></td>
<td></td>
<td></td>
<td>M99293</td>
</tr>
</tbody>
</table>
function such as activation, motion, or migration, usually along a chemokine concentration gradient; and varies depending on the chemokine bound and the cell type (27).

Some chemokine receptors have a role in infectious disease susceptibility or pathogenesis. Several of the CC or CXC receptors are used by HIV-1 or HIV-2 as entry cofactors (Table 1). DARC serves as a cofactor for entry of Plasmodium vivax into erythrocytes (29); and as is the case with the 32bp-deleted CCR5 and HIV, resistance to P. vivax malaria is associated with lack of DARC expression (29), probably due to polymorphism of the DARC gene promoter (30). Several viruses (Epstein-Barr virus, cytomegalovirus, and Herpes virus samiri) contain functional homologues of human chemokine receptors, which suggests that the viruses may use these receptors to subvert the effects of host chemokines (27). They may also serve as HIV entry cofactors for human cells, as observed for HCMV-US28 (31).

### Chemokine Receptors and HIV Infection

The first clue that chemokine-related events were important in HIV pathogenesis came from work in R. Gallo’s laboratory, which showed that high levels of chemokines could inhibit HIV replication in vitro (32). Then a cohort of highly exposed, HIV-negative men had high circulating levels of several chemokines, such as RANTES, MIP-1α, and MIP-1β (8). These data led to the hypothesis that chemokines might prevent HIV infection by binding to the elusive HIV entry cofactor. Since the discovery of CD4 in the 1980s as an HIV receptor, it had become apparent that other factors were required for HIV to enter cells. For example, mouse cells expressing CD4 could not be infected with HIV (33). Using a novel cloning strategy, E. Berger and colleagues first demonstrated in May 1996 that CXCR4, a chemokine receptor for which no ligand had yet been determined, was an entry cofactor for T-cell tropic or syncytium-inducing (SI) viruses (34).

### Table 1. Human chemokine receptors (continued from p. 2)

<table>
<thead>
<tr>
<th>Receptors (Old names)a</th>
<th>Ligands</th>
<th>Predominant expression/ Tissue distribution</th>
<th>Chromosomal location</th>
<th>GenBank Acc. #</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC/CXC Receptor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DARC (Duffy antigen)</td>
<td>RANTES, MCP-1, TARC etc.</td>
<td>IL-8, MGSA, gro-α etc.</td>
<td>Plasmodium vivax</td>
<td>1 U01839</td>
</tr>
<tr>
<td>ChemR1</td>
<td>ND ND</td>
<td>T lymphocytes, polymorphonuclear cells</td>
<td>HIV-1 3 U73529</td>
<td></td>
</tr>
<tr>
<td>CMKBR1</td>
<td>ND ND</td>
<td>neutrophils, monocytes, brain, liver, lung, skeletal muscles</td>
<td>HIV-1 N/A X17403</td>
<td></td>
</tr>
<tr>
<td>V28</td>
<td>ND ND</td>
<td>Neural and lymphoid tissue</td>
<td>3p21 U20350</td>
<td></td>
</tr>
<tr>
<td>D2S201E</td>
<td>ND ND</td>
<td>wide, including cells of hemopoietic origin</td>
<td>2q21 M99293</td>
<td></td>
</tr>
<tr>
<td>B1R1</td>
<td>ND ND</td>
<td>B lymphocytes</td>
<td>X68149</td>
<td></td>
</tr>
<tr>
<td>EB1</td>
<td>ND ND</td>
<td>B lymphocytes</td>
<td>L08176</td>
<td></td>
</tr>
<tr>
<td>GPR1.5</td>
<td>ND ND</td>
<td></td>
<td>L36149</td>
<td></td>
</tr>
</tbody>
</table>

a New nomenclature for CC and CXC chemokine receptors was adopted at the Gordon Research Conference on Chemotactic Cytokines, June 23–28, 1996. b Pathogens using this receptor for infection. c The 32bp deleted allele of CCR5 has been referred to as CCR5-2 (13). d Chemokine receptor-like genes whose predicted proteins have 7 transmembrane domains.

Abbreviations: BLR1, Burkitt’s lymphoma receptor-1; CMKBR1, Chemokine ß receptor-like-1; DARC, duffy antigen/receptor for chemokines; EB1, Epstein-Barr virus-induced receptor; ENA78, epithelial-derived neutrophil-activating peptide-78; GPR, G protein coupled receptor; gro, growth related gene product; HCMV, human cytomegalovirus; HUMSTR, human serum transmembrane segment receptor; IL, interleukin; IP-10, interferon-gamma inducible 10kD protein; LESTR, leukocyte-expressed seven-transmembrane-domain receptor; MCP, monocyte chemotactic protein; Mig, monokine induced by interferon gamma; MIP, macrophage inflammatory protein; NSI, non-syncytium inducing; N/A, not applicable; NAP-2, neutrophil-activating protein-2; ND, not determined; RANTES, regulated on activation, normal T cell expressed and secreted; SDF-1, stromal cell-derived factor-1; STRL33, seven transmembrane-domain receptor from lymphocyte clone 33; TARC, thymus and activation regulated chemokine.
Emerging Infectious Diseases Vol. 3, No. 3, July–September 1997

Perspectives

Figure 1. Predicted structure and amino acid sequence of CCR5. The typical serpentine structure is depicted with three extracellular (top) and three intracellular (bottom) loops and seven transmembrane (TM) domains. The shaded horizontal band represents the cell membrane. Amino acids are listed with a single letter code. Residues that are identical to those of CCR2b are indicated by dark shading, and highly conservative substitutions are indicated by light shading. Extracellular cysteine residues are indicated by bars, and the single N-linked glycosylation consensus site is indicated by an asterisk. Reprinted and modified with permission from the authors and Cell (39). Copyright (1996) Cell Press.

Shortly before this, Samson et al. had cloned CCR5 (then known as CC-CKR5) and shown that its ligands included RANTES, MIP-1α, and MIP-1β (35). These data encouraged several groups to examine the role of CCR5 in HIV entry, and within weeks of the CXCR4 publication, five additional publications reported CCR5 and CCR3 as HIV entry cofactors for macrophage-tropic or non-syncytium-inducing (NSI) viruses (33,36-39) and CCR3 and CCR2b as entry factors for dual tropic HIVs (38,39). Recent studies of brain-derived microglial cells have shown that CCR5 and CCR3 permit entry of HIV into these cells (40). The tropism of HIV strains appears to be determined in part by the way they use chemokine receptors (Table 1, Figure 2). In peripheral blood, although both T cells and monocytes express CXCR4 and CCR5 (41), HIV strains that use CXCR4 tend to infect predominantly T cells, while strains that use CCR5 infect T cells and monocytes. This tropism correlates with the ability of the virus to induce syncytia in T-cell lines. SI viruses (often present late in the course of HIV infection), tend to be CXCR4 tropic, while NSI viruses (which appear to be the viruses transmitted in vivo) tend to be CCR5 tropic (33,34,36-39). However, some primary SI viruses can use either CXCR4 or CCR5 (42), and some may use both coreceptors, as well as CCR2b or CCR3 (39). When classified based on chemokine receptor use, HIV types are independent of their genetic relatedness (43).

The exact mechanism by which HIV interacts with CXCR4 or CCR5 and by which this interaction, together with CD4 binding, leads to virus entry has not been clearly defined (44). It appears to involve the interactions of the V3 loop and other parts of the outer envelope protein gp120 (45-47) with extracellular domains of CCR5 or CCR2b (48,49) and may involve multistep

Figure 2. Chemokine receptors and cell tropism of HIV. Three cell types are illustrated, an in vitro passaged T-cell line (Tl), a monocyte/macrophage (M), and a circulating T-cell (T). T-cell lines express CXCR4 but not CCR5; macrophages and circulating peripheral blood T-cells express both receptors, although the amounts of CXCR4 are lower on macrophages (as indicated by the small CXCR4 symbol). M-tropic HIV, because of certain envelope amino acid sequences, binds to CCR5 and can enter both macrophages and circulating T cells. T-tropic HIV preferentially binds CXCR4 and enters T cells or T-cell lines. After binding to the chemokine receptor and to CD4, the viruses enter by fusion with the cell membrane. Cells with the 32bp deleted form of CCR5 do not express cell surface CCR5, and, although M-tropic HIV can bind CD4, it cannot enter the cell. If the cells express CXCR4, they can still be infected with T-tropic viruses (not shown). Note that this figure does not depict the actual size relationships of the proteins, cells, or viruses.
interactions with CD4, the chemokine receptor, and other cell surface components (50). Chemo-
kines may inhibit HIV entry through receptor blockade, desensitization, sequestration, or internal-
ization; through alterations in receptor affinity; or by inhibiting postbinding steps (51), such as
phosphorylation, through G-coupled mechanisms.

Chemokine Receptor Gene Polymorphism and Susceptibility to HIV Infection

In 1995 and 1996, researchers at the Aaron Diamond AIDS Research Center began studies of
highly HIV-exposed seronegative men whose cells produced high levels of chemokines in vitro
(8,52). Cells from several of these men were not infectable with primary or NSI type viruses, but
were infectable with SI viruses (52). These data suggested some protective mechanism related to
the CCR5 rather than to the CXCR4 receptor because of the chemokine ligand profile of the
CCR5 receptor (Table 1) and stimulated studies that led to the cloning and restriction digestion of
CCR5 in these persons (52). The novel deletion of 32bp in CCR5 reported by Liu et al. (9) in August
1996, to be present in three of the 15 HIV-exposed but seronegative men was also independently
reported in September by Samson et al. (16) and Dean et al. (17; Table 2). In these studies, the
distribution of homozygosity and heterozygosity of the deleted allele, in small and large cross-
sectional or prospective studies of HIV-unexposed, -exposed, or -infected persons (mainly European
or North American Caucasians) strongly sup-
ported the protective effect of the deletion. Since
these initial observations, several studies of
other populations have reported the same
finding: an enrichment of the homozygous Δ32/
Δ32 CCR5 genotype in highly HIV-exposed per-
sons who remain uninfected (12,18,19; Table 2).
In persons with well-documented HIV exposure,
the prevalence of homozygosity for the Δ32/Δ32
CCR5 genotype increases with increasing HIV
exposure (12), the wild type and Δ32 CCR5 alleles
(referred to by some as CCR5-1 and CCR5-2 [19])
can be easily detected by polymerase chain
reaction (PCR) techniques, with or without enzy-
matic digestion (9,12,16,17), or more recently, by
heteroduplex studies (19). An example of the
results of a PCR followed by restriction digestion
is given in Figure 3. Persons who are homozygous
for the wild type CCR5 (W) or the allele with the
32 bp deletion (Δ32) or heterozygous for both
alleles can be easily distinguished because the
deleted fragment reduces the size of the
amplified product (Figure 3).

The 32 bp deletion occurs at a site of a repeat
motif in the CCR5 gene (16; Figure 4) and results
in a frame shift in the coding sequence that pro-
duces a defective CCR5, which is not expressed
on the surface of cells (Figures 2 and 5). The dele-
tion results in the loss of three of the seven trans-
membrane domains, two of the three outer loops,
and the intracellular signaling domain (Figure 5).

Does the CCR5 32 Bp Deletion Provide
Absolute Protection Against HIV
Infection?

The genetic link to remaining HIV-negative
in spite of continued HIV exposure was the
subject of much discussion during the summer
and fall of 1996. Was the protection absolute?
Who should be tested for the gene? Would
persons told they were homozygous for the dele-
tion engage in high-risk behavior more frequently?
Although at that point no one homozygous for the
deletion had been found HIV-positive, the fact
that CXCR4 gene and several other chemokine
receptors could mediate HIV entry suggested
caution in assuming that persons with the CCR5
Δ32/Δ32 genotype would be absolutely resistant
to HIV infection. Since then, three HIV-
infected persons with this genotype have been
reported (20-22; Table 2); for one, the mode of
Table 2. Population studies of CCR5 genotypes

<table>
<thead>
<tr>
<th>Author</th>
<th>Population</th>
<th>Ethnicity</th>
<th>Status</th>
<th>No.</th>
<th>% (No.)</th>
<th>(\Delta 32) allele freq. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liu et al. (9)</td>
<td>High-risk, USA</td>
<td>Caucasian</td>
<td>Neg</td>
<td>15</td>
<td>80.0 (12)</td>
<td>20.0 (3) 0.200</td>
</tr>
<tr>
<td>General, USA</td>
<td>Caucasian</td>
<td>Neg</td>
<td>122</td>
<td>80.3 (98)</td>
<td>19.7 (24) 0.098</td>
<td></td>
</tr>
<tr>
<td>General, S. Amer.</td>
<td>Venezuelan</td>
<td>Neg</td>
<td>46</td>
<td>100 (46)</td>
<td>0 (0) 0 0</td>
<td></td>
</tr>
<tr>
<td>Samson et al. (16)</td>
<td>General, Europe</td>
<td>Caucasian</td>
<td>Neg</td>
<td>704</td>
<td>82.7 (582)</td>
<td>16.2 (114) 1.1 (8) 0.092</td>
</tr>
<tr>
<td>General, Asia</td>
<td>Japanese</td>
<td>Neg</td>
<td>248</td>
<td>100 (248)</td>
<td>0 (0) 0 0</td>
<td></td>
</tr>
<tr>
<td>General, Africa</td>
<td>Ctrl/W. African</td>
<td>Neg</td>
<td>124</td>
<td>100 (124)</td>
<td>0 (0) 0 0</td>
<td></td>
</tr>
<tr>
<td>AIDS clinics, Paris</td>
<td>Caucasian</td>
<td>Pos</td>
<td>723</td>
<td>89.2 (645)</td>
<td>10.8 (78) 0 (0) 0.054</td>
<td></td>
</tr>
<tr>
<td>Dean et al. (17)</td>
<td>High-risk, USA</td>
<td>Mixed</td>
<td>Neg</td>
<td>883</td>
<td>81.9 (724)</td>
<td>15.6 (138) 2.4 (21) 0.10</td>
</tr>
<tr>
<td>High-risk, USA</td>
<td>Mixed</td>
<td>Pos</td>
<td>1883</td>
<td>85.9 (1618)</td>
<td>14.0 (264) 0.0005 (1) 0.071</td>
<td></td>
</tr>
<tr>
<td>High-risk, USA</td>
<td>African-Amer.</td>
<td>Mixed</td>
<td>Neg</td>
<td>620</td>
<td>96.6 (599)</td>
<td>3.4 (21) 0 (0) 0.017</td>
</tr>
<tr>
<td>High-risk, USA</td>
<td>Caucasian</td>
<td>Mixed</td>
<td>1250</td>
<td>100</td>
<td>0 (0) 0 (0) 0</td>
<td></td>
</tr>
<tr>
<td>Low-risk, USA</td>
<td>Caucasian</td>
<td>Pos</td>
<td>143</td>
<td>100</td>
<td>0 (0) 0 (0) 0</td>
<td></td>
</tr>
<tr>
<td>Huang et al. (12)</td>
<td>High-risk, USA</td>
<td>Caucasian</td>
<td>Pos</td>
<td>461</td>
<td>79.8 (368)</td>
<td>20.2 (93) 0 (0) 0.101</td>
</tr>
<tr>
<td>High-risk, USA</td>
<td>Caucasian</td>
<td>Neg</td>
<td>446</td>
<td>78.0 (348)</td>
<td>16.7 (82) 3.6 + 0.128</td>
<td></td>
</tr>
<tr>
<td>Blood donors, USA</td>
<td>Caucasian, 95%</td>
<td>Neg</td>
<td>637</td>
<td>85.2 13.3</td>
<td>1.4 0.08</td>
<td></td>
</tr>
<tr>
<td>General, Africa</td>
<td>Black</td>
<td>Mixed</td>
<td>137</td>
<td>100</td>
<td>0 (0) 0 (0) 0</td>
<td></td>
</tr>
<tr>
<td>China/Thailand/other</td>
<td>Caucasian</td>
<td>Pos</td>
<td>191</td>
<td>100</td>
<td>0 (0) 0 (0) 0</td>
<td></td>
</tr>
<tr>
<td>Michael et al. (18)</td>
<td>High-risk, USA</td>
<td>Mixed</td>
<td>Pos</td>
<td>406</td>
<td>87.5 (348)</td>
<td>14.3 (58) 0 (0) 0.071</td>
</tr>
<tr>
<td>High-risk, USA</td>
<td>Mixed</td>
<td>Neg</td>
<td>21</td>
<td>71.4 (15)</td>
<td>9.5 (2) 19.1 (4) 0.238</td>
<td></td>
</tr>
<tr>
<td>Intermed.-risk, USA</td>
<td>Mixed</td>
<td>Neg</td>
<td>240</td>
<td>78.3 (188)</td>
<td>20.4 (49) 1.3 (3) 0.115</td>
<td></td>
</tr>
<tr>
<td>Bitti et al. (20)</td>
<td>High-risk, Australia</td>
<td>Caucasian</td>
<td>Pos</td>
<td>265</td>
<td>N/A</td>
<td>N/A 0.004 (1) 0</td>
</tr>
<tr>
<td>Theodoru et al. (22)</td>
<td>High-risk, Europe</td>
<td>Pos</td>
<td>412</td>
<td>N/A</td>
<td>N/A</td>
<td>0.002 (1) N/A</td>
</tr>
<tr>
<td>Eugenolsen et al. (23)</td>
<td>High-risk, Denmark</td>
<td>Caucasian</td>
<td>Neg</td>
<td>35</td>
<td>74 (26)</td>
<td>20 (7) 6 (2) 0.157</td>
</tr>
<tr>
<td>High-risk, Denmark</td>
<td>Caucasian</td>
<td>Pos</td>
<td>99</td>
<td>78 (77)</td>
<td>22 (22) 0 0.111</td>
<td></td>
</tr>
<tr>
<td>Blood donors, Denmark</td>
<td>Caucasian</td>
<td>Neg</td>
<td>37</td>
<td>73 (27)</td>
<td>24 (9) 3 (1) 0.149</td>
<td></td>
</tr>
<tr>
<td>Zimmerman et al. (19)</td>
<td>Blood donors, N. America</td>
<td>Caucasian</td>
<td>Neg</td>
<td>387</td>
<td>77.5 (300)</td>
<td>21.7 (84) 0.8 (3) 0.116</td>
</tr>
<tr>
<td>Blood donors, India</td>
<td>Tamil</td>
<td>Neg</td>
<td>87</td>
<td>83.9 (73)</td>
<td>12.6 (11) 3.4 (3) 0.098</td>
<td></td>
</tr>
<tr>
<td>Blood donors, W. Africa</td>
<td>Black</td>
<td>Neg</td>
<td>40</td>
<td>100 (40)</td>
<td>0 (0) 0 (0) 0</td>
<td></td>
</tr>
<tr>
<td>High risk, USA</td>
<td>Caucasian</td>
<td>Pos</td>
<td>614</td>
<td>77.4 (475)</td>
<td>22.6 (139) 0 (0) 0.113</td>
<td></td>
</tr>
<tr>
<td>High risk, USA</td>
<td>African-Am.</td>
<td>Neg</td>
<td>294</td>
<td>94.2 (277)</td>
<td>5.8 (17) 0 (0) 0.29</td>
<td></td>
</tr>
<tr>
<td>High risk, USA</td>
<td>Hispanic</td>
<td>Neg</td>
<td>290</td>
<td>92.8 (269)</td>
<td>6.9 (20) 0.3 (1) 0.38</td>
<td></td>
</tr>
<tr>
<td>High risk, USA</td>
<td>Asian</td>
<td>Neg</td>
<td>164</td>
<td>99.4 (163)</td>
<td>0.6 (1) 0 (0) 0.003</td>
<td></td>
</tr>
<tr>
<td>High risk, USA</td>
<td>Native Amer.</td>
<td>Neg</td>
<td>87</td>
<td>83.9 (73)</td>
<td>12.6 (11) 3.4 (3) 0.098</td>
<td></td>
</tr>
<tr>
<td>High risk, USA</td>
<td>Caucasian</td>
<td>Pos</td>
<td>111</td>
<td>73.9 (82)</td>
<td>21.6 (24) 4.5 (5) 0.153</td>
<td></td>
</tr>
<tr>
<td>High risk, USA</td>
<td>African-Am.</td>
<td>Neg</td>
<td>2</td>
<td>50.0 (1)</td>
<td>0 (0) 0.250</td>
<td></td>
</tr>
<tr>
<td>High risk, USA</td>
<td>Hispanic</td>
<td>Neg</td>
<td>12</td>
<td>91.7 (11)</td>
<td>8.3 (1) 0 (0) 0.042</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) CCR5 genotypes: W/W, homozygous wild type; W/\(\Delta 32\), heterozygous wild type/32bp deletion; \(\Delta 32/\Delta 32\), homozygous for the 32 bp deletion.

\(^b\) Numbers updated to include additional Multicenter Hemophilia Cohort Study patients studied by O’Brien et al. (21) and Dean et al. (pers. comm.).

\(^c\) Not available.
entry cofactors, even non-SI viruses might be 
CCR5 receptors (CCR3 and CCR2b) are also HIV 
the SI virus phenotype, i.e., viruses that most 
other two was homosexual behavior (20,22). 
sequences isolated from these persons suggested 
the deleted nucleotides are represented in noncapitalized font. 
transmission was most likely blood products (21), 
while the only reported exposure risk for the 
transmission was most likely blood products (21),

Figure 4. Partial CCR5 gene and amino acid sequence with 32 bp deletion. 
Nucleotide sequence of the CCR5 gene surrounding the deleted region, and 
translation into the normal receptor (top lines) or the truncated mutant (Δ 32 CCR5, bottom lines). The 10-bp direct repeat is represented in bold italics and the deleted nucleotides are represented in noncapitalized font.

Figure 5. Predicted structure and amino acid sequence of the mutant form of human CCR5. The mutant protein lacks the last three transmembrane segments of CCR5, as well as the regions involved in G-protein coupling. The transmembrane organization is given by analogy with the predicted transmembrane structure of the wild-type CCR5, although the correct maturation of the mutant protein up to the plasma membrane has not been demonstrated. The shaded horizontal band represents membrane(s) of intracellular organelles. Amino acids represented in italics and dark shading correspond to unnatural residues resulting from the frame shift caused by the deletion. Figures 4 and 5 reprinted and modified with permission from the authors and Nature (16) Copyright (1996) Macmillan Magazines Ltd.

Perspectives

Does CCR5 Gene Polymorphism Determine All Resistance to HIV?

The highest reported prevalence of homozygosity for the Δ32 CCR5 allele deletion in persons highly exposed to HIV but uninfected is 33% (9,12). However, most (96% according to one estimate [19]) highly exposed HIV-seronegative persons are not homozygous for the Δ32 CCR5 allele. Moreover, among exposed but persistently HIV-seronegative persons in Africa and Thailand, no one positive for the Δ32 CCR5 allele has been found (CDC unpub. data; S. Rowland-Jones, F. Plummer, pers. comm.). These data suggest that many mechanisms may contribute to remaining seronegative despite high HIV exposure: chemokine-related mechanisms, such as altered CCR5 levels on the cell surface (53) or the level of circulating chemokines; other immune system genes, such as those of the HLA system (10,11,14); and immune responses, such as those of cytotoxicT cells (7,15). The relative importance of these mechanisms in populations with differing modes of exposure or genetic backgrounds needs to be elucidated.

CCR5 Polymorphism and Its Interaction with Other Factors in the Course of HIV Disease

Several large studies of the effect of CCR5 genotypes on the course of HIV disease have been published (Table 2). Dean et al. examined the course of HIV (time to AIDS) in several U. S. populations with different exposure to HIV (homosexuals, intravenous drug users, persons with hemophilia) and found that persons with one copy of the deleted CCR5 gene had a delayed (approximately 2 years longer) progression to AIDS when compared with those with the homozygous wild type genotype (17). Similar findings have been reported (19,23) in Caucasian HIV-positive homosexual men. Another study of HIV-positive homosexuals did not find such a striking effect of heterozygosity, although progression to AIDS was again slowed (12). One clue
to the varying effects of the heterozygous CCR5 genotype on progression to AIDS in different groups comes from another U. S. study of male homosexuals, in which men with one copy of the Δ32 CCR5 genotype had delayed progression to AIDS, particularly if their circulating viruses were of the NSI phenotype (18). Paradoxically, once AIDS is diagnosed, persons with one copy of Δ32 CCR5 may have a more rapid disease course.1 Thus, the effect of the CCR5 genotype on disease progression may depend on the phenotype and chemokine receptor use of circulating viruses. The finding that microglial cells can be infected with HIV through CCR3- or CCR5-dependent mechanisms (40) also suggests that the clinical spectrum of HIV disease may also depend on the CCR5 genotype.

Thus, complex interactions between virus and host chemokine receptor genotype and virus and cell chemokine receptor phenotype exist. Studies to elucidate the interaction of these genotypes with each other, with virus phenotypes, and with other factors that influence the course of HIV disease are ongoing (24,25). Preliminary data from the Multi Center AIDS Cohort Study suggest that the effect of CCR5 and HLA genotype on survival or disease course are independent and that the effect of HLA on disease outcomes may be greater than the effect of CCR5 genotype (54).

Population Studies of CCR5 Genotypes
The distribution of the 32bp deletion in different populations is summarized in Table 2. Among Caucasians in North America or Europe, the prevalence of homozygosity for the 32 bp deletion is approximately 1%, and 10% to 20% are heterozygous. In smaller numbers of non-Caucasians, heterozygosity is found in approximately 6% of African-Americans, 7% of Hispanics, 13% of Native Americans, and fewer than 1% of Asians (17,19; CDC, unpub. data). Several studies of non-Caucasian populations including persons from parts of Africa (Zaire, Burkina Faso, Cameroon, Senegal, Benin, Uganda, Rwanda, Kenya, Malawi, Tanzania, Sierre Leone) (12,16,19), Haiti (12), parts of Asia (Thailand, India, China, Korea, Japan, the Philippines) (12,16,19; CDC, unpub. data), and Venezuela (9) have not found the 32 bp deletion among the HIV-infected or -uninfected persons tested (Table 2). One additional study (of more than 3,000 persons) found similar global distributions of CCR5 genotypes (and noted a decreasing frequency from north to south in Europe and Asia).2

Other Chemokine Receptor Polymorphisms
Several other point mutations in CCR5 have been observed (17), but their population prevalence and their role in HIV infection or disease progression have not been reported. No polymorphisms in CXCR4 have been reported to date. CCR3 has two alleles (S or T at position 276) (55-57), and similarly, the population prevalence of these alleles and their role in HIV infection have not yet been determined.

Implications for Management and Understanding of the Global HIV Epidemic
The discovery of the role of chemokine receptors as coreceptors, along with CD4, for HIV entry has led to a burgeoning of public and private research in HIV pathogenesis, new therapies, and new approaches to vaccines (52,58). For example, in addition to the classification of HIV types on the basis of genetic or neutralization phenotype relatedness, a new virus classification made on the basis of their receptor use has emerged. New therapies based on receptor mimics, receptor ligands, chemokines, or chemokine analogs are being developed and tested in vitro. Genetic engineering with chemokine receptors is being used to develop animal models for HIV transmission and disease progression. And, in the arena of vaccines, a new concept has developed: the induction of high levels of HIV-blocking chemokines such as RANTES, MIP-1α, and MIP-1β as desirable properties of an HIV vaccine.

New treatments and prevention measures for HIV raise ethical, social, and legal issues that also relate to a number of other infectious and chronic diseases (e.g., malaria, breast cancer, and diabetes) as new genes influencing the risk for these diseases are discovered. Should all

---


persons at risk for HIV infection be tested for CCR5 gene polymorphism? Should persons homozygous for the Δ32 CCR5 genotype receive specific counseling regarding their risk for HIV and other sexually transmitted infections? If a person is heterozygous and infected with HIV, should HIV treatment be altered? Could knowledge of one’s genotype favorably or unfavorably influence health insurance, life insurance, or employment opportunities? As a result of these questions, educational materials have become available for the public and public health professionals.3

Another finding that provoked discussion was the uneven distribution of the genotype across geographic and racial groups. One hypothesis was that some previous epidemic, restricted to Europe, had led to a survival advantage among persons homozygous or heterozygous for the CCR5 Δ32 genotype and had resulted in a concentration of the CCR5 Δ32 genotype in persons of European ancestry. The “black death” of Northern Europe (1347-1350) and other large epidemics have been used as examples (59,60). Thus, certain populations appear to have an increased survival advantage in the new HIV epidemic. Conversely, populations with lower prevalence of the Δ32 CCR5 genotype might be expected to have a higher prevalence of HIV infection or a more rapid course of the epidemic. In the United States, a greater risk for HIV infection has been found among African-Americans than among Caucasians, when known risk factors, including social class, were controlled (61). The prevalence of the Δ32 CCR5 allele is lower in African-Americans than in Caucasians. While increasing HIV prevalence in parts of Asia and Africa may be attributed to social and demographic factors, as well as differences in the phenotype of circulating viruses (62), the racial distribution of HIV risk raises the possibility that differences in the distribution of the Δ32 CCR5 allele or other heritable host factors might influence the rate of transmission or the speed of the epidemic in different racial groups.

Conclusions

These findings have defined a new role for a gene that normally controls cell migration; have identified new alleles of the gene that determines whether someone becomes infected with HIV and how the disease progresses once infection has occurred; and have identified several other new HIV-receptors that mediate viral entry into different cell types. The findings have precipitated new classifications of HIV phenotypes by cell tropism and receptor use and opened new areas for drug and vaccine development. These findings have also enhanced other research: studies of host factors affecting the acquisition and clinical course of infectious diseases, the differential distribution of genetic characteristics in populations and their potential effects on health status, the translation of genetics research into public health measures, and the social implications of genetic differences affecting illness and death caused by infectious and other diseases.

Acknowledgments

We thank J.S. McDougal and Renu Lal for critical discussion, Clair Kiernan for assistance with graphics, and Wendy Paris for secretarial help.

Dr. McNicholl is a scientist in the Immunology Branch, Division of AIDS, STD, TB, and Laboratory Research, NCID, CDC, and an Assistant Professor of Medicine (Rheumatology) and Pathology at Emory University. Her research includes immunogenetics and T cell antigen recognition in infectious and autoimmune diseases, and their application to vaccines. In collaboration with other scientists at CDC and in Thailand, she is investigating immunologic and genetic explanations for apparent resistance to HIV of highly exposed persistently seronegative commercial sex workers in Thailand. She also serves as the NCID coordinator for CDC genetics activities.

References


Centers for Disease Control and Prevention. Facts about CCR5 and protection against HIV-1 infection; 1997.
Emerging Infectious Diseases Vol. 3, No. 3, July–September 1997


